HIGHFDA DRUG

Lanreotide Injection recall: Cipla USA lanreotide acetate pre-filled syringes recalled for sterility

Cipla USA, Inc. recalls lanreotide acetate 120 mg/0.5 mL pre-filled syringes distributed nationwide due to lack of assurance of sterility after FDA observations at the contract manufacturer. Health care providers and patients should stop use immediately and contact Cipla or their clinician for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 13, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
March 13, 2026
Hazard Level
HIGH
Brands
LANREOTIDE ACETATE, Cipla USA Inc.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
PREGNANT, GENERAL, ELDERLY

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
LANREOTIDE ACETATE, Cipla USA Inc.
Product type
Lanreotide Injection (pre-filled syringe)
Model numbers
Lot, expiry: 4401699IR1, Exp. 5/31/2026, 4401699IR2, Exp. 5/31/2026, 4401700IR1, Exp. 5/31/2026, 4401701IR1 +12 more
UPC codes
69097-906, 69097-907, 69097-908, 69097-907-67, 69097-908-67, 69097-906-67
Sizes
120 mg/0.5 mL
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 13, 2026

  2. Reported by FDA DRUG

    April 15, 2026

  3. RecallRadar source check

    April 22, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance. Notification method: Letter

About This Product

Lanreotide acetate is used to treat acromegaly and neuroendocrine tumors. It is administered via subcutaneous injection.

Why This Is Dangerous

Sterility issues can lead to bacterial contamination or infection at the injection site or systemically.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Immediate stop-use instructions; potential infection risk requires medical consultation.

Practical Guidance

How to identify if yours is affected

  1. Check NDC 69097-906-67 on the box and syringe label.
  2. Review lot numbers listed in recall materials.
  3. Check expiry date on each lot (5/31/2026).

Where to find product info

FDA enforcement report D-0423-2026 and Cipla recall communications.

What timeline to expect

Recall processing timelines vary; expect formal notification by letter.

If the manufacturer is unresponsive

  • Document all contact attempts.
  • Escalate to Cipla customer service and your healthcare provider.
  • File a report with the FDA if necessary.

How to prevent similar issues

  • Verify sterility for all injectable medications when receiving from a provider.
  • Ensure supplier is legitimate and recalls are acknowledged before administration.

Documentation advice

Keep recall letter, packaging, lot numbers, and any medical records related to administration.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Lanreotide Injection, 120 mg/0.5 mL. Box contains 1 pre-filled syringe. Single-dose only. Rx only. Manufactured by Pharmathen International S.A., Rodopi, Greece. Manufactured for Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC 69097-906-67. Expiry dates and lot numbers vary by unit.

Reported Incidents

No incidents or injuries are described in the provided document. The recall status is ACTIVE with HIGH hazard level.

Key Facts

  • Multiple Lot numbers with expiry 5/31/2026
  • Exp 5/31/2026 for listed lots
  • 4401699IR1 to 4401732IR1 lot series
  • Manufactured for Cipla USA, Warren NJ

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
PREGNANTGENERALELDERLYPREGNANTPETS
Injury Types
POISONINGELECTRICAL

Product Details

Model Numbers
Lot
expiry: 4401699IR1
Exp. 5/31/2026
4401699IR2
Exp. 5/31/2026
+15 more
UPC Codes
69097-906
69097-907
69097-908
+3 more
Affected States
ALL
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Cipla USA Recalls Lanthanum Carbonate Tablets Over Stability Issues

Cipla USA recalled 1,180 boxes of Lanthanum Carbonate chewable tablets on October 24, 2025. The recall follows a failure to meet stability specifications for hardness tests. Consumers and healthcare providers must stop using the product immediately.

LANTHANUM CARBONATE
Failed stability
Read more